Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Non-Comparative, Phase II Study of ZD1839 (Iressa) as First-Line Treatment in Subjects With Relapsed Prostate Cancer Following Radical Prostatectomy or Radiotherapy

NCT00241475 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00241475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00241475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Non-Comparative, Phase II Study of ZD1839 (Iressa) as First-Line Treatment in Subjects With Relapsed Prostate Cancer Following Radical Prostatectomy or Radiotherapy
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2003
Completion date
October 31, 2005
Enrollment
30
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer